1. P234 QVA149 once daily improves lung function, dyspnoea and health status independent of prior medications and disease severity: the SHINE study. (14th November 2013) Authors: Chapman, KR; Bateman, ED; Gallagher, N; Hu, H; Banerji, D Journal: Thorax Issue: Volume 68(2013)Supplement 3 Page Start: A182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P233 Efficacy and safety of once-daily glycopyrronium compared with blinded tiotropium in patients with COPD: the GLOW5 study. (14th November 2013) Authors: Chapman, KR; Beeh, K; Bateman, ED; Beier, J; D'Urzo, AD; Nutbrown, R; Chen, H; Henley, M; Overend, T; D'Andrea, P Journal: Thorax Issue: Volume 68(2013)Supplement 3 Page Start: A182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P237 Comparison of COPD exacerbations with once-daily QVA149 versus twice-daily salmeterol/fluticasone combination: the ILLUMINATE study. (14th November 2013) Authors: Vogelmeier, C; Bateman, ED; Chen, H; Banerji, D Journal: Thorax Issue: Volume 68(2013)Supplement 3 Page Start: A184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P148 Once-daily tiotropium Respimat® add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma. (12th November 2015) Authors: Halpin, D; Bateman, ED; Paggiaro, P; Bleecker, ER; Engel, M; Moroni-Zentgraf, P; Schmidt, H; Kerstjens, HAM Journal: Thorax Issue: Volume 70(2015)Supplement 3 Page Start: A151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. S92 Efficacy Of Once-daily Tiotropium Respimat® 5 µg From Five Phase Iii Trials In Adults With Symptomatic Asthma. (10th November 2014) Authors: Price, D; Bateman, ED; Paggiaro, P; Kaplan, A; Engel, M; Schmidt, H; Moroni-Zentgraf, P; Kerstjens, HAM Journal: Thorax Issue: Volume 69(2014)Supplement 2 Page Start: A50 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P149 Once-daily tiotropium Respimat® add-on to at least ICS in adult patients with symptomatic asthma: pooled safety analysis. (12th November 2015) Authors: Dusser, D; Buhl, R; Castro, M; Kerstjens, HAM; Paggiaro, P; Engel, M; Moroni-Zentgraf, P; Unseld, A; Bateman, ED Journal: Thorax Issue: Volume 70(2015)Supplement 3 Page Start: A151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P163 Tiotropium decreases the risk of exacerbations in patients with symptomatic asthma regardless of baseline characteristics including markers of allergic status. (14th November 2013) Authors: Halpin, DMG; Bateman, ED; Tashkin, DP; Engel, M; Dahl, R; Paggiaro, P; Beck, E; Vandewalker, M; Seibold, W; Moroni-Zentgraf, P; Schmidt, H; Kerstjens, HAM Journal: Thorax Issue: Volume 68(2013)Supplement 3 Page Start: A149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗